Anticardiolipin and antinuclear antibodies in cancer patients--a case control study

J B Armas, J Dantas, D Mendonça, R Farto, M Ribeiro, G Herrero-Beaumont, J Gouveia, N J McHugh

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

OBJECTIVE: To investigate patients with cancer for the frequency of IgG and IgM aCL and ANA in comparison to a group of age- and sex-matched controls.

METHODS: Serum levels of IgG and IgM anticardiolipin antibodies (aCL), antinuclear antibodies (ANA) and anticytoplasmic antibodies were evaluated in 145 cancer patients, including 20 patients with thromboembolic disease (TED) and compared with age- and sex-matched controls.

RESULTS: Higher levels of IgG aCL were found in patients compared to controls (p < 0.02). However, there appeared to be no difference in serum aCL levels between TED and the remaining cancer patients. No difference was found in the frequency of antinuclear and anticytoplasmic antibodies between patients and controls and the autoantibody presence in patients was usually not associated with concomitant autoimmune disease.

CONCLUSION: Apart from increased levels of non-thrombogenic associated IgG aCL, there was no evidence for significantly enhanced B cell autoreactivity in this large collection of cancer patients compared to controls.
Original languageEnglish
Pages (from-to)227-232
Number of pages6
JournalClinical and Experimental Rheumatology
Volume18
Issue number2
Publication statusPublished - 2000

Fingerprint

Anticardiolipin Antibodies
Antinuclear Antibodies
Case-Control Studies
Neoplasms
Immunoglobulin G
Immunoglobulin M
Serum
Autoantibodies
Autoimmune Diseases
B-Lymphocytes
Age Groups
Antibodies

Cite this

Armas, J. B., Dantas, J., Mendonça, D., Farto, R., Ribeiro, M., Herrero-Beaumont, G., ... McHugh, N. J. (2000). Anticardiolipin and antinuclear antibodies in cancer patients--a case control study. Clinical and Experimental Rheumatology, 18(2), 227-232.

Anticardiolipin and antinuclear antibodies in cancer patients--a case control study. / Armas, J B; Dantas, J; Mendonça, D; Farto, R; Ribeiro, M; Herrero-Beaumont, G; Gouveia, J; McHugh, N J.

In: Clinical and Experimental Rheumatology, Vol. 18, No. 2, 2000, p. 227-232.

Research output: Contribution to journalArticle

Armas, JB, Dantas, J, Mendonça, D, Farto, R, Ribeiro, M, Herrero-Beaumont, G, Gouveia, J & McHugh, NJ 2000, 'Anticardiolipin and antinuclear antibodies in cancer patients--a case control study', Clinical and Experimental Rheumatology, vol. 18, no. 2, pp. 227-232.
Armas JB, Dantas J, Mendonça D, Farto R, Ribeiro M, Herrero-Beaumont G et al. Anticardiolipin and antinuclear antibodies in cancer patients--a case control study. Clinical and Experimental Rheumatology. 2000;18(2):227-232.
Armas, J B ; Dantas, J ; Mendonça, D ; Farto, R ; Ribeiro, M ; Herrero-Beaumont, G ; Gouveia, J ; McHugh, N J. / Anticardiolipin and antinuclear antibodies in cancer patients--a case control study. In: Clinical and Experimental Rheumatology. 2000 ; Vol. 18, No. 2. pp. 227-232.
@article{27cd5269a2c14f4ead4c063d9adc0a44,
title = "Anticardiolipin and antinuclear antibodies in cancer patients--a case control study",
abstract = "OBJECTIVE: To investigate patients with cancer for the frequency of IgG and IgM aCL and ANA in comparison to a group of age- and sex-matched controls. METHODS: Serum levels of IgG and IgM anticardiolipin antibodies (aCL), antinuclear antibodies (ANA) and anticytoplasmic antibodies were evaluated in 145 cancer patients, including 20 patients with thromboembolic disease (TED) and compared with age- and sex-matched controls. RESULTS: Higher levels of IgG aCL were found in patients compared to controls (p < 0.02). However, there appeared to be no difference in serum aCL levels between TED and the remaining cancer patients. No difference was found in the frequency of antinuclear and anticytoplasmic antibodies between patients and controls and the autoantibody presence in patients was usually not associated with concomitant autoimmune disease. CONCLUSION: Apart from increased levels of non-thrombogenic associated IgG aCL, there was no evidence for significantly enhanced B cell autoreactivity in this large collection of cancer patients compared to controls.",
author = "Armas, {J B} and J Dantas and D Mendon{\cc}a and R Farto and M Ribeiro and G Herrero-Beaumont and J Gouveia and McHugh, {N J}",
year = "2000",
language = "English",
volume = "18",
pages = "227--232",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "2",

}

TY - JOUR

T1 - Anticardiolipin and antinuclear antibodies in cancer patients--a case control study

AU - Armas, J B

AU - Dantas, J

AU - Mendonça, D

AU - Farto, R

AU - Ribeiro, M

AU - Herrero-Beaumont, G

AU - Gouveia, J

AU - McHugh, N J

PY - 2000

Y1 - 2000

N2 - OBJECTIVE: To investigate patients with cancer for the frequency of IgG and IgM aCL and ANA in comparison to a group of age- and sex-matched controls. METHODS: Serum levels of IgG and IgM anticardiolipin antibodies (aCL), antinuclear antibodies (ANA) and anticytoplasmic antibodies were evaluated in 145 cancer patients, including 20 patients with thromboembolic disease (TED) and compared with age- and sex-matched controls. RESULTS: Higher levels of IgG aCL were found in patients compared to controls (p < 0.02). However, there appeared to be no difference in serum aCL levels between TED and the remaining cancer patients. No difference was found in the frequency of antinuclear and anticytoplasmic antibodies between patients and controls and the autoantibody presence in patients was usually not associated with concomitant autoimmune disease. CONCLUSION: Apart from increased levels of non-thrombogenic associated IgG aCL, there was no evidence for significantly enhanced B cell autoreactivity in this large collection of cancer patients compared to controls.

AB - OBJECTIVE: To investigate patients with cancer for the frequency of IgG and IgM aCL and ANA in comparison to a group of age- and sex-matched controls. METHODS: Serum levels of IgG and IgM anticardiolipin antibodies (aCL), antinuclear antibodies (ANA) and anticytoplasmic antibodies were evaluated in 145 cancer patients, including 20 patients with thromboembolic disease (TED) and compared with age- and sex-matched controls. RESULTS: Higher levels of IgG aCL were found in patients compared to controls (p < 0.02). However, there appeared to be no difference in serum aCL levels between TED and the remaining cancer patients. No difference was found in the frequency of antinuclear and anticytoplasmic antibodies between patients and controls and the autoantibody presence in patients was usually not associated with concomitant autoimmune disease. CONCLUSION: Apart from increased levels of non-thrombogenic associated IgG aCL, there was no evidence for significantly enhanced B cell autoreactivity in this large collection of cancer patients compared to controls.

M3 - Article

VL - 18

SP - 227

EP - 232

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 2

ER -